LIP
ORMP icon

Lighthouse Investment Partners’s Oramed Pharmaceuticals ORMP Stock Holding History

Lighthouse Investment Partners’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,227
Closed -$207K – 349
2022
Q4 		$207K Buy
+17,227
New +$134K 0.02% 206

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lighthouse Investment Partners's ORMP Position: Q1 2023 in Review

Lighthouse Investment Partners sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 17,227 shares — an estimated $207K sold.

Lighthouse Investment Partners first reported a position in ORMP in Q4 2022 and held it in 1 quarter. The position peaked at $207K in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Lighthouse Investment Partners reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Lighthouse Investment Partners sold 17,227 Oramed Pharmaceuticals shares in Q1 2023, an estimated $207K.
  • Lighthouse Investment Partners first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Lighthouse Investment Partners's Oramed Pharmaceuticals position peaked at $207K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Lighthouse Investment Partners's 13F filing for Q1 2023, filed 15 May 2023.